Delta 4
Main Menu
Main Menu

Pipeline Services

Your Drug Discovery & Development Pipeline — Enhanced

Clients come to us to help enhance their drug development pipeline making it more efficient, less risky, more actionable, and more likely to succeed. By leveraging Delta4’s AI-driven solutions, pharmaceutical companies can benefit from:

delta-4-icon-red

Reduced discovery and development time:

Hyper-C analyzes data and identifies potential drug candidates faster than traditional methods, accelerating the entire process.
delta-4-icon-red

Increased probability of success:

Focusing on drug targets with high potential and utilizing existing drugs with known safety profiles minimizes risks.
delta-4-icon-red

Increased drug discovery efficiency:

Drug indication expansion through Hyper-C allows for more efficient utilization of existing resources and knowledge.
delta-4-icon-red

Clear mechanism of action hypotheses:

Delta4's platform provides transparent insights into how drugs work, which is valuable for regulatory requirements.
delta-4-icon-red

Biomarker identification for efficient clinical trials:

By identifying potential biomarkers, Delta4 supports more targeted and efficient clinical trials.
Delta4-Teamfotos-Wien-Studio-Matphoto-272

Solutions for Each Step of Your Pipeline

Delta4’s combined expertise in AI, computational biology, and drug development offers a comprehensive solution for enhancing drug discovery and development pipelines at every stage.

Identification of Drug Target

Delta4’s AI-powered platform, Hyper-C, analyzes vast datasets, including scientific literature, clinical trials, patents, and omics datasets. Allowing it to rapidly identify and prioritize disease-modifying drug targets. By focusing on targets with the greatest potential for effectiveness, it helps reduce development time and cost.

The platform identifies beneficial drug-disease matches by aligning networks representing drug mechanisms of action and disease pathophysiology.

How We Can Help

  • Identify and rank disease-modifying drug targets
  • Find or expand indications for your existing drug or drug target
  • Propose prognostic and predictive protein biomarkers

Real-World Results

For example, we used Hyper-C to identify clopidogrel, a platelet inhibitor drug, as a potential treatment for focal segmental glomerulosclerosis (FSGS), a rare kidney disease.
We’ve also published a full report on how we leveraged Hyper-C to identify potential new indications for the anti-inflammatory drug Igratimod. This process involved creating a molecular model of Iguratimod’s mechanism of action and screening it against our extensive disease phenotype library.

Drug Screening and Design

Our platform can be used to screen for completely novel compounds that act on identified targets. We evaluate the molecular neighborhood and downstream consequences of drug candidates, providing insights into their mechanisms of action. By analyzing each drug’s mechanism of action in the context of existing treatments, Hyper-C allows for the identification of potential drug combinations.

How We Can Help

  • Mechanistic evaluation of indications
  • Side Effect & Drug-Drug Interaction (DDI) Modeling
  • Drug Combination Analysis

Real-World Results

We used Hyper-C to identify nine drugs that could potentially be used to treat COVID-19. Seven of these drugs were later found to be effective by other researchers.

Scientists Working
A hand holding a blood test tube on a blue background.

Preclinical Testing

Our expertise extends to proposing prognostic and predictive protein biomarkers. This aids in streamlining and designing preclinical studies. We offer support in selecting appropriate preclinical models to test the effects of identified drug candidates.

How We Can Help

  • Identification of the most fitting in-vitro and animal models
  • Partnerships with prestigious labs and medical universities in Europe

Real-World Results

Our work on FSGS demonstrates our capabilities at this stage. After identifying clopidogrel as a potential treatment candidate, we conducted preclinical animal studies to validate its effectiveness. The results showed that it improved proteinuria in the animal model, supporting its potential as a new treatment for FSGS.

Clinical Trials

We help optimize clinical trials for a higher probability of success. Our AI-powered platform can analyze clinical trial data and provide insights that support decision-making during clinical development.

How We Can Help

  • Access to key opinion leaders in various disease areas for the optimal planning and set-up of the clinical trial protocol
  • Partnerships with prestigious medical universities in Austria and Germany

Real-World Results

Delta4’s work with FSGS has progressed to the clinical trial planning phase. We have published a potential trial protocol and are ready to recruit patients for a phase 2 trial to test clopidogrel’s effectiveness in humans.

prahmaceutic doing tests
A person with glasses and a blue hoodie is sitting at a table, engaged in conversation.

Patenting Opportunities

We maximize your ability to find novel applications for existing drugs for which the literature lacks direct evidence. Uncovering these novel applications, we help our clients obtain stronger patent protection for repurposed drugs, even if the original substance patents have expired. This is because the novelty of the use case can be patented rather than just the substance itself.

How We Can Help

  • Identifying novel applications for existing drugs with strong patent potential
  • Providing precise mechanisms of action to support patent claims and regulatory requirements
  • Identifying and prioritizing novel drug targets for patent protection

Real-World Results

An example of this is our work with clopidogrel. We identified a new use for this drug in treating FSGS and obtained a second medical use patent for this application.

AI Power, Expert Knowledge, Real-World Success

At Delta4, we combine innovative AI technology with deep scientific expertise to produce real-world success. Our proprietary platform, Hyper-C, delivers powerful AI-driven insights, but we don’t stop there. Every result is meticulously verified and curated by a team of experts and computational biologists with strong scientific backgrounds. We ensure that our discoveries go beyond theoretical AI extrapolations and are followed through to real-world applications, achieving meaningful results for our partners.

Interested in learning more about Delta4’s scientific achievements? Visit our Publications and Research page to explore our proven results and research.

Our Partners & Clients

Green abstract logo with the word "Pharma" written in black next to it.
At 4P-Pharma, our foundation is based on scientific rationale. Delta4 has provided us with this essential foundation for our co-development project, enabling us to start from the mechanism of action in the disease. This approach allows us to more accurately and quickly identify and validate therapeutic targets, making our drug development process more efficient and focused.
Revital RattenbachCEO 4P-Pharma
The Delta4 team members are highly competent in big data network analyses both from the disease side and from the drug product and pharmacology side. Their methodology of marrying one with the other led us to new intellectual property.
Johan HäggbladPhD, Chief Scientific Officer at Calliditas Therapeutics
This innovative methodology has enabled us to identify therapeutic targets that have never been described before for specific indications.
Revital RattenbachCEO 4P-Pharma
Thanks to DELTA4, we have been able to speed up the selection of preclinical models, that will allow us to effectively prove the beneficial effects of those drug candidates.
Revital RattenbachCEO 4P-Pharma
Their reporting is thorough and to the point. We highly recommend Delta4 as an AI partner for drug discovery and development.
Johan HäggbladPhD, Chief Scientific Officer at Calliditas Therapeutics
...allowing us to progress in bringing new drugs to patients suffering from serious, untreated diseases.
Revital RattenbachCEO 4P-Pharma
Previous
Next

Proud Member of Scientist.com

Streamlining Transparency and Cooperation

Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.

“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com

Are you a member of Scientist.com? View Our Profile

Get Involved

Learn how you can contribute to the exciting work happening at Delta4

Careers

Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.
Explore Careers

Investors

Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.
Get In Touch

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.
Partner With Us